Article

FDA clears femtosecond laser platform

The FDA has cleared a new femtosecond laser platform (Femto LDV Z Models, Ziemer Ophthalmic Systems). The platform has been released globally.

Silver Spring, MD-The FDA has cleared a new femtosecond laser platform (Femto LDV Z Models, Ziemer Ophthalmic Systems AG). The platform has been released globally.

“We are looking forward to presenting the products and their unique features to the U.S. audience,” said Graham Hodge, managing director for Ziemer USA Inc. All models are now available for sale in the United States.

The three models in the product line (Z2, Z4, and Z6) are designed to perform a broad variety of procedures in ocular surgery. A practice can start with a lower-level model and upgrade on-site by adding modules as its needs change.

The highest-level model (Z6) is cleared for the creation of corneal incisions in patients undergoing LASIK surgery, tunnel creation for the implantation of intra-corneal rings, and pocket creation for the implantation of corneal implants. This model also can perform lamellar and penetrating keratoplasties or other treatments requiring lamellar resection of the cornea at varying depths.

The mid-level model (Z4) has fewer features, whereas the entry-level model (Z2) is designed to meet everyday LASIK needs.

For more information, visit www.femtoldv.com/z-models.htmlor call 866/708-4490.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
© 2025 MJH Life Sciences

All rights reserved.